Investor Relations
中 ｜ EN
Investor Relations 中 EN

About the Disease – Multiple Myeloma (MM)

Multiple myeloma is caused by the dysregulated proliferation of plasma cells, characterized by the proliferation of monoclonal plasma cells that results in an overabundance of monoclonal immunoglobulin or its fragment (M protein). Clinical manifestations of MM include hypercalcemia, renal insufficiency, anemia, and the destruction of the bone. 1,2 MM primarily occurs in the elderly population. In the Chinese population, MM is the second most common hematologic malignancy, 3,4 with a median age of onset of 59 years1 and an incidence rate of 1.46 per 100,0004 that is lower than that of western countries. Although MM remains an incurable disease, the introduction of new therapies and diagnostic tools have led to significant advances in the clinical management of MM. The current standard of care therapies for MM include proteasome inhibitors, immunomodulatory agents, monoclonal antibodies and XPO1 inhibitors.1,2,5,6

Clinical Manifestations
Hypercalcemia
Renal insufficiency
Anemia
Bone destruction 1,2
10
  • Account for 10% of all hematologic malignancies
  • The second most common hematologic malignancy¹'³
1
  • Account for 1% of all malignancies
Although MM remains an incurable disease, standard of care
therapies may turn it into a manageable chronic condition¹'²

1. Q&A about Multiple Myeloma 2020
2. Guidelines for the Diagnosis and Treatment of Multiple Myeloma (2022 revision)
3. Guan N, LI X, Wang S, et al. Incidence of Multiple Myeloma in Shenyang from 2009 to 2014. Cancer Research on Prevention and Treatment, 2019, 46(06): 547-550.
4. https://gco.iarc.fr/today/fact-sheets-populations
5. Wang D, Hao Y, Xiao M, et al. Epidemiology and etiology of multiple myeloma. Inter J Epidemionl Infect Dis, 2018,45(4): 277-280.
6. Version 5.2022,03/09/22 ⓒ 2021 National Comprehensive Cancer NetworkⓇ(NCCNⓇ)

About the Disease – Diffuse Large B-Cell Lymphoma (DLBCL)

Diffuse large B-cell lymphoma (DLBCL) is one of the most common types of non-Hodgkin lymphoma (NHL) in adults and a highly heterogeneous malignancy in both clinical manifestations and prognosis. DLBCL accounts for 30%-40% of all NHL cases, and over 40% in most Asian countries. 1,2

The most common symptom of DLBCL is painless and progressive swelling of lymph nodes. Around 30% of patients with DLBCL experience B symptoms (fever, weight loss, and night sweats). Approximately 40% of DLBCLs originate from extranodal sites, and the most common extranodal sites are the gastrointestinal tract and bone marrow. 3

Currently, patients with DLBCL can achieve total remission after the first-line treatment with the R-CHOP regimen, with the other 40%-50% eventually relapsing or becoming refractory. Among those patients with relapsed/refractory DLBCL, approximately 10% can recover after standard salvage therapies and autologous hematopoietic stem cell transplantation, while the other 90% still face a poor prognosis. 4

Relative Incidence Rates of B-Cell Lymphomas in China1
Relative Incidence Rates of B-Cell Lymphomas in the World2
1. Li X, Li G, Gao Z, et al. Distribution pattern of lymphoma subtypes in China: A nationwide multicenter study of 10002 cases. Journal of Diagnostics Concepts & Practice. 2012,11(2):111-115.
2. Perry AM, Diebold J, Nathwani BN, et al. Non-Hodgkin lymphoma in the developing world: review of 4539 cases from the International Non-Hodgkin Lymphoma Classification Project. Haematologica. 2016;101(10):1244-1250.
3. Ansell SM. Non-Hodgkin lymphoma: diagnosis and treatment. Mayo Clin Proc. 2015;90(8):1152–1163
4. Clémentine Sarkozy, Laurie H. Sehn. New drugs for the management of relapsed or refractory diffuse large B-cell lymphoma. Ann Lymphoma 2019;3:10.
For more information about our product, please click to enter >>

XPOVIO®(selinexor)

The world’s first oral selective inhibitor of the
nuclear export protein with a novel mechanism
of action

The information provided below is for healthcare professionals only, and the drug
may have not been approved in all the countries where this website is accessible.

Selinexor has been approved in a host of countries and regions including the U.S., the EU, Mainland China, Australia, and
Singapore. Antengene has the exclusive right to research, develop and commercialize selinexor in Greater China
(mainland China, Hong Kong, Taiwan, Macau), Australia, New Zealand, South Korea, and the ten ASEAN countries.

XPOVIO®(selinexor)
Download the Product Insert
(for healthcare professionals only)

Product information stated in the National Medical Product Administration’s Database of Approved Drugs in China

[Product Name]

Chinese generic name:塞利尼索片

Chinese brand name:希维奥®

English generic name:Selinexor Tablets 

Generic name in Pinyin: Sailinisuo Pian

[Indication]*
In combination with dexamethasone for the treatment of adults with relapsed or refractory multiple myeloma who have received prior therapies including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody
[Strength per Tablet] 20mg

[Packaging] 12 tablets/carton (3 tablets/blister, 4 blisters/carton), 16 tablets/carton (4 tablets/blister, 4 blisters/carton)

[Shelf Life]  48 months

[Applicable Product Standard]  Product standard for imported drugs JX20210104

[Approval Number] NDA Approval Number HJ20210083


*XPOVIO (selinexor) Mainland China Product Information


Please see product insert for information related to dosing, adverse events, prohibited uses, warnings and precautions.

The information provided below is for healthcare professionals only, and the drug may have not been approved in all the countries where this website is accessible.

If you are a healthcare professional,
please click “Confirm” to proceed with the download
Otherwise please click “Cancel”

Confirm
Cancel

The above product information is intended for use by healthcare professionals only. The above products may not have been approved and/or licensed for marketing in all countries where this website is accessible.

XPOVIO®(selinexor)
Download the Product Insert
(for healthcare professionals only)

Product information stated in the National Medical Product Administration’s Database of Approved Drugs in China

[Product Name]

Chinese generic name:塞利尼索片

Chinese brand name :希维奥®

English generic name:Selinexor Tablets 

Generic name in Pinyin: Sailinisuo Pian

[Indication]*

As a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who had received at least two lines of systemic therapy.

[Strength per Tablet] 20mg

[Packaging] 12 tablets/carton, 16 tablets/carton, 20 tablets/carton, 32 tablets/carton

[Shelf Life] 60 months

[Applicable Product Standard] Product standard for imported drugs JX20210104

[Approval Number] NDA Approval Number HJ20210083


*XPOVIO (selinexor) Mainland China Product Information


Please see product insert for information related to dosing, adverse events, prohibited uses, warnings and precautions.

The information provided below is for healthcare professionals only, and the drug may have not been approved in all the countries where this website is accessible.

If you are a healthcare professional,
please click “Confirm” to proceed with the download
Otherwise please click “Cancel”

Confirm
Cancel

The above product information is intended for use by healthcare professionals only. The above products may not have been approved and/or licensed for marketing in all countries where this website is accessible.

XPOVIO® (selinexor) ETC (Orphan drug)
Download the Product Insert
(for healthcare professionals only)
[The ingredients]
1tablet (167.2mg)
[Active ingredient]
selinexor∙∙∙ 20mg
[Inactive ingredients]
colloidal silicon dioxide, croscarmellose sodium, magnesium stearate, microcrystalline cellulose, Opadry 200 clear, Opadry II blue, povidone K30, and sodium lauryl sulfate
[Appearance] blue, round, film‐coated tablets
[Indications And Usage]*

1. XPOVIO in combination with dexamethasone is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody.

2. XPOVIO is indicated the treatment of adult patients with relapsed or refractory diffuse large B‐cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma, after at least 2 lines of systemic therapy.


*XPOVIO (selinexor) South Korea Product Information


Please see product insert for information related to dosing, adverse events, prohibited uses, warnings and precautions.

If you are a healthcare professional,
please click “Confirm” to proceed with the download
Otherwise please click “Cancel”

Confirm
Cancel

The above product information is intended for use by healthcare professionals only. The above products may not have been approved and/or licensed for marketing in all countries where this website is accessible.

XPOVIO® (selinexor) ETC (Orphan drug)
Download the Product Insert
(for healthcare professionals only)

XPOVIO (selinexor) Film Coated Tablet 20mg
FULL PRESCRIBING INFORMATION*

[Multiple Myeloma]
• XPOVIO in combination with bortezomib and dexamethasone is indicated for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.
• XPOVIO in combination with dexamethasone is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti‐CD38 monoclonal antibody.
[Diffuse Large B‐Cell Lymphoma]
XPOVIO is indicated for the treatment of adult patients with relapsed or refractory diffuse large B‐cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma, after at least 2 lines of systemic therapy who are not eligible for haematopoietic cell transplant [see Clinical Studies (14.2)].
[Dosage Forms And Strengths]

Tablets: 20 mg, blue, round, bi‐convex, film‐coated tablets with “K20” debossed on one side and nothing on the other side.


*XPOVIO (selinexor) Singapore Product Information

Please see product insert for information related to dosing, adverse events, prohibited uses, warnings and precautions.

If you are a healthcare professional,
please click “Confirm” to proceed with the download
Otherwise please click “Cancel”

Confirm
Cancel

The above product information is intended for use by healthcare professionals only. The above products may not have been approved and/or licensed for marketing in all countries where this website is accessible.

XPOVIO® (selinexor)
Download the Product Insert
(for healthcare professionals only)

Selinexor 20mg Oral Tablets

[NAME OF THE MEDICINE] Selinexor

[THERAPEUTIC INDICATIONS]*

XPOVIO is indicated:

•In combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.

•In combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least three prior therapies and whose disease is refractory to at least one proteasome inhibitor, at least one immunomodulatory medicinal product (IMiD), and an anti-CD38 monoclonal antibody (mAb).


*XPOVIO (selinexor) Australian Product Information

If you are a healthcare professional,
please click “Confirm” to proceed with the download
Otherwise please click “Cancel”

Confirm
Cancel

The above product information is intended for use by healthcare professionals only. The above products may not have been approved and/or licensed for marketing in all countries where this website is accessible.

XPOVIO®(selinexor)
Download the Product Insert
(for healthcare professionals only)

Selinexor 20mg Film Coated Tablets

FULL PRESCRIBING INFORMATION*


[Multiple Myeloma]

•In combination with dexamethasone (Xd) for the treatment of adult patients withrelapsed/refractory multiple myeloma (R/R MM) who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors (PIs), at least two immunomodulatory agents (IMiDs), and an anti-CD38 monoclonal antibody.

•In combination with bortezomib and dexamethasone (XVd) for the treatment of adult patients with MM who have received at least one prior therapy.


[Diffuse Large B‐Cell Lymphoma]

as a monotherapy for the treatment of adult patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma, after at least 2 lines of systemic therapy.

The fast-tracked approval for this indication is based on the tumor response rate (see section 14.2 for clinical studies). This indication still needs to undergo a confirmatory study in order to validate clinical benefits.


[Dosage Forms And Strengths]

Tablets: 20 mg, blue, round, bi‐convex, film‐coated tablets with “K20” debossed on one side and nothing on the other side.


* XPOVIO (selinexor) Taiwan Product Information


Please see product insert for information related to dosing, adverse events, prohibited uses, warnings and precautions.

If you are a healthcare professional,
please click “Confirm” to proceed with the download
Otherwise please click “Cancel”

Confirm
Cancel

The above product information is intended for use by healthcare professionals only. The above products may not have been approved and/or licensed for marketing in all countries where this website is accessible.

XPOVIO®(selinexor)
Download the Product Insert
(for healthcare professionals only)

XPOVIO Tablets 20mg


[Indications And Usage] *

• in combination with dexamethasone for the treatment of multiple myeloma in adult patients who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, two immunomodulatory agents and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.


[Pharmaceutical Form]

Film-coated tablet. Blue, round, bi-convex, film-coated tablet (4 mm thick and 7 mm in diameter) with “K20” debossed on one side.


* XPOVIO (selinexor) Hong Kong Product Information


Please see product insert for information related to dosing, adverse events, prohibited uses, warnings and precautions.

If you are a healthcare professional,
please click “Confirm” to proceed with the download
Otherwise please click “Cancel”

Confirm
Cancel

The above product information is intended for use by healthcare professionals only. The above products may not have been approved and/or licensed for marketing in all countries where this website is accessible.

XPOVIO®(selinexor)
Download the Product Insert
(for healthcare professionals only)

XPOVIO Tablets 20mg


[Indications And Usage] *

• in combination with dexamethasone for the treatment of multiple myeloma in adult patients who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, two immunomodulatory agents and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.


[Pharmaceutical Form]

Film-coated tablet. Blue, round, bi-convex, film-coated tablet (4 mm thick and 7 mm in diameter) with “K20” debossed on one side.


* XPOVIO (selinexor) Macau Product Information


Please see product insert for information related to dosing, adverse events, prohibited uses, warnings and precautions.

If you are a healthcare professional,
please click “Confirm” to proceed with the download
Otherwise please click “Cancel”

Confirm
Cancel

The above product information is intended for use by healthcare professionals only. The above products may not have been approved and/or licensed for marketing in all countries where this website is accessible.

XPOVIO®(selinexor)
Download the Product Insert
(for healthcare professionals only)

XPOVIO 20 mg film-coated tablets


[Therapeutic Indication]*

• in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.

• in combination with dexamethasone for the treatment of multiple myeloma in adult patients who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, two immunomodulatory agents and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.


*XPOVIO (selinexor) Malaysia Product Information


Please see product insert for information related to dosing, adverse events, prohibited uses, warnings and precautions.

If you are a healthcare professional,
please click “Confirm” to proceed with the download
Otherwise please click “Cancel”

Confirm
Cancel

The above product information is intended for use by healthcare professionals only. The above products may not have been approved and/or licensed for marketing in all countries where this website is accessible.

XPOVIO®(selinexor)
Download the Product Insert
(for healthcare professionals only)

XPOVIO 20 mg film-coated tablets


[Therapeutic Indication]*

• in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.

• in combination with dexamethasone for the treatment of multiple myeloma in adult patients who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, two immunomodulatory agents and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.


*XPOVIO (selinexor) Thailand Product Information


Please see product insert for information related to dosing, adverse events, prohibited uses, warnings and precautions.


If you are a healthcare professional,
please click “Confirm” to proceed with the download
Otherwise please click “Cancel”

Confirm
Cancel

The above product information is intended for use by healthcare professionals only. The above products may not have been approved and/or licensed for marketing in all countries where this website is accessible.

XPOVIO® (selinexor) exerts
antitumor effects through three mechanistic pathways

1

Selinexor exerts antitumor effects by inducing the accumulation and activation of tumor suppressor proteins in the nucleus1, 4-7

2

Selinexor induces the accumulation of oncogenic mRNA in the nucleus, thus lowering the intracellular level of oncogenic proteins2

3

Selinexor restores the sensitivity to glucocorticoid by activating the glucocorticoid receptor pathway3

1.Kashyap T,et al.Oncotarget.2016;7(48):78883-78895 2.Gandhi UH,et al.Clin Lymphoma Myeloma Leuk.2018;18(5):335-345 3.Arguta C,et al.Oncotarget.2018 May 22;9(39):25529-25544 4.Nachmias B,et al.Leukemia.2020 Nov;34(11):2875-2886 5.TaiYT,et al.Leukemia.2014;28(1):155-165 6.Gupta A,et al.J Thorac Oncol.2017;12(9):1446-1450 7.Salas Fragomeni RA, el al.Mol Cancer Ther.2013Jul;12(7):1171-9

Scientific Publications

{{item.article_des}}

Learn More
For more product news,please click to enter >>

Report adverse events
Should you suspect any adverse events associated with our products, please contact us at:

Should you need any medical information
related to our products,
please contact us at:

Since you have reported adverse events related to Antengene’s products, your/the patient’s information will be disclosed to Antengene’s pharmacovigilance (PV) department and entered into Antengene’s PV database which will also be reported to relevant authorities as required by related laws and regulations. Antengene may follow-up with you and/or the patient on the events you reported.


If you contact us via the hotline or E-mail, we will assume that you are aware of and consented to our collection and handling of your information. Your personal information will be strictly protected in accordance with Antengene’s privacy policies.

Privacy Notice

Privacy Notice

Last updated: July 15, 2022

This Privacy Notice describes Our policies and procedures on the collection, use and disclosure of Your information when You use the Service, and tells You about Your privacy rights and how the law protects You.

We use Your Personal data to provide and improve the Service. By using the Service, You agree to the collection and use of information in accordance with this Privacy Notice. If You do not agree to these terms, You are not authorized to use Our Service.

1. Definitions

The following definitions shall have the same meaning regardless of whether they appear in singular or in plural.

For the purposes of this Privacy Notice:

Affiliate means with respect to a specified person or entity, any other person or entity that directly, or indirectly through one or more intermediaries, controls or is controlled by, or is under common control with, the specified person or entity, and the term “control” (including the terms controlling, controlled by and under common control with) means the possession, direct or indirect, of (i) the power to direct or cause the direction of the management and policies of an entity, whether through the ownership of voting securities, by contract or otherwise or (ii) 50% or more of the issued share capital of an entity.

Antengene (referred to as either "Antengene", "We", "Us" or "Our" in this Agreement) refers to Antengene Corporation Limited and its Affiliates.

Cookies are small files that are placed on Your computer, mobile device or any other device by a website, containing the details of Your browsing history on that website among its many uses.

Device means any device that can access the Service such as a computer, a cellphone or a digital tablet.

Personal Information is any information that relates to an identified individual or can be used to identify a person, either directly or indirectly (e.g. by combining different sets of indirect indentifiers).

Service refers to the Website and its mobile applications.

Service Provider means any third party that processes Personal Information under the instructions of Antengene or to which Antengene discloses information for use on Antengene’s behalf.

Usage Data refers to data collected automatically, either generated by the use of the Service or from the Service infrastructure itself (for example, the duration of a page visit).

Website refers to Antengene Website, accessible from antengene.com

You means the individual accessing or using the Service, or the legal entity on behalf of which such individual is accessing or using the Service, as applicable.

2. Information We Collect

2.1 Personal Information

While using Our Service, We may ask You to provide Us with certain personally identifiable information that can be used to contact or identify You. Personally identifiable information may include, but is not limited to Your name, postal address, telephone number, email address, date of birth, identification numbers, and health, financial and professional information.

2.2 Usage Data

Usage Data is collected automatically when using the Service.

a) Usage Data may include information such as Your Device's Internet Protocol address (e.g. IP address), browser type, browser version, the pages of our Service that You visit, the time and date of Your visit, the time spent on those pages, unique device identifiers and other diagnostic data.

b) When You access the Service by or through a mobile device, We may collect certain information automatically, including, but not limited to, the type of mobile device You use, Your mobile device unique ID, the IP address of Your mobile device, Your mobile operating system, the type of mobile Internet browser You use, unique device identifiers and other diagnostic data.

c) We may also collect information that Your browser sends whenever You visit our Service or when You access the Service by or through a mobile device.

2.3 Tracking Technologies and Cookies

We use Cookies and similar tracking technologies to track the activity on Our Service and store certain information. Tracking technologies used are beacons, tags, and scripts to collect and track information and to improve and analyze Our Service. The technologies We use may include:

a) Cookies or Browser Cookies. A cookie is a small file placed on Your Device. You can instruct Your browser to refuse all Cookies or to indicate when a Cookie is being sent. However, if You do not accept Cookies, You may not be able to use some parts of our Service. Unless you have adjusted Your browser setting so that it will refuse Cookies, our Service may use Cookies.

b) Flash Cookies. Certain features of our Service may use local stored objects (or Flash Cookies) to collect and store information about Your preferences or Your activity on our Service. Flash Cookies are not managed by the same browser settings as those used for Browser Cookies.

c) Web Beacons. Certain sections of our Service and our emails may contain small electronic files known as web beacons (also referred to as clear gifs, pixel tags, and single-pixel gifs) that permit Antengene, for example, to count users who have visited those pages or opened an email and for other related website statistics (for example, recording the popularity of a certain section and verifying system and server integrity).

3. Use of Your Personal Information

3.1 Antengene may use Personal Information for the following purposes:

a) To provide and maintain our Service, including to monitor the usage of our Service, site administration and maintenance, and security improvements.

b) To provide You with general health information (such as information on certain health conditions) as well as information about Our products and services;.

c) To respond to Your requests: To attend and manage Your requests, inquiries, or applications to Us.

d) For business transfers: We may use Your information to evaluate or conduct a merger, divestiture, restructuring, reorganization, dissolution, or other sale or transfer of some or all of Our assets, whether as a going concern or as part of bankruptcy, liquidation, or similar proceeding, in which Personal Information held by Us about our Service users is among the assets transferred.

e) For other purposes: We may use Your information for other purposes where it is necessary for Our legitimate interest as a company, including but not limited to research and development, regulatory reporting, contract management, fulfillment, analytics, fraud prevention, corporate governance, reporting, legal compliance, data analysis, identifying usage trends, determining the effectiveness of our promotional campaigns and to evaluate and improve our Service, products, services, marketing and your experience.

3.2 We will not sell, share, or otherwise distribute Your Personal Information to third parties except as provided in this Privacy Notice. We may share Your Personal Information in the following situations:

a) With Service Providers: We may share Your Personal Information with Service Providers for further processing, such as to monitor and analyze the use of our Service, or to contact You. These Service Providers have contracted with Us to only use the Personal Information for the purpose(s) for which the data were originally collected or may otherwise be lawfully processed, not to sell Your Personal Information to other third parties, and not to disclose it to other third parties except as may be required by law, as permitted by Us or as stated in this Privacy Policy.

b) For business transfers: We may share or transfer Your Personal Information in connection with, or during negotiations of, any merger, sale of Antengene assets, financing, or acquisition of all or a portion of Our business to another company.

c) With Affiliates: We may share Your information with Our Affiliates, in which case we will require those Affiliates to honor this Privacy Notice.

d) With Your consent: We may disclose Your Personal Information for any other purpose with Your consent.

 

3.3 Retention of Your Personal Information

a) Antengene will retain Your Personal Information only for as long as is necessary for the purposes set out in this Privacy Notice. We will retain and use Your Personal Information to the extent necessary to comply with our legal obligations (for example, if we are required to retain your data to comply with applicable laws), resolve disputes, and enforce our legal agreements and policies.

b) Antengene will also retain Usage Data for internal analysis purposes. Usage Data is generally retained for a shorter period of time, except when this data is used to strengthen the security or to improve the functionality of Our Service, or We are legally obligated to retain this data for longer time periods.

4. Sharing Your Personal Information

4.1 Your information, including Personal Information, is processed at Antengene's operating offices and in any other places where the parties involved in the processing are located. It means that this information may be transferred to — and maintained on — computers located outside of Your state, province, country or other governmental jurisdiction where the data protection laws may differ than those from Your jurisdiction. Therefore, by using the Service or otherwise providing information to Us, You hereby expressly consent to the transfer of Your Personal Information outside Your country or region.

4.2 If Antengene is involved in a merger, acquisition or asset sale, Your Personal Information may be transferred. We will provide notice before Your Personal Information is transferred and becomes subject to a different Privacy Notice.

4.3 Under certain circumstances, Antengene may be required to disclose Your Personal Information if required to do so by law or in response to valid requests by public authorities (e.g. a court or a government agency).

4.4 Antengene may disclose Your Personal Information in the good faith belief that such action is necessary to:

a) Comply with a legal obligation;

b) Protect and defend the rights or property of Antengene;

c) Prevent or investigate possible wrongdoing in connection with the Service;

d) Protect the personal safety of Users of the Service or the public;

e) Protect against legal liability

5. Data Security

The security of Your Personal Information is important to Us, and We use commercially reasonable administrative, technical, personnel-related, and physical security measures designed to safeguard the Personal Information in Our possession against loss, theft and unauthorized use, disclosure, or modification. But remember that no method of transmission over the Internet, or method of electronic storage is 100% secure. We cannot guarantee its absolute security. In the event of a security incident involving Your Personal Information, as required by applicable laws, We will inform You in a timely manner and report the incident to relevant regulatory authorities.

6. Children's Privacy

We are committed to protecting the privacy of children. The Service is not intended for, or designed to attract, children under the age of 18. We do not knowingly collect personally identifiable information from anyone under the age of 18. If You are a parent or guardian and You are aware that Your child has provided Us with Personal Information, please contact Us. If We become aware that We have collected Personal Information from anyone under the age of 18 without verification of parental consent, We take steps to remove that information from Our servers.

7. Links to Other Websites

7.1 Our Service may contain links to other websites that are not operated by Us. If You click on a third-party link, You will be directed to that third party's site. We strongly advise You to review the Privacy Notice of every site You visit.

7.2 We have no control over and assume no responsibility for the content, privacy policies or practices of any third-party sites or services.

8. Changes to this Privacy Notice

8.1 We may update Our Privacy Notice from time to time. We will notify You of any changes by posting the new Privacy Notice on this page.

8.2 We will let You know via email and/or a prominent notice on Our Service, prior to the change becoming effective and update the "Last updated" date at the top of this Privacy Notice.

8.3 You are advised to review this Privacy Notice periodically for any changes. Changes to this Privacy Notice are effective when they are posted on this page.

9. Contact Us

You may contact us at any time if You have questions about this Privacy Notice.  Under applicable data protection laws, You may have the right to object to or request restriction of processing of Your Personal Information and to request access to, rectification, erasure and portability of the Personal Information We hold about You, subject to certain exceptions prescribed by law.  To reach Us, please send an email to: privacy@antengene.com, and we shall endeavor to answer Your inquiry as soon as reasonably possible in compliance with applicable laws.


Terms of Use

Terms and Conditions

Last updated: July 15, 2022

Please read these Terms and Conditions carefully before using Our Service.

1. Definitions

The following definitions shall have the same meaning regardless of whether they appear in singular or in plural.

For the purposes of these Terms and Conditions:

Affiliate means with respect to a specified person or entity, any other person or entity that directly, or indirectly through one or more intermediaries, controls or is controlled by, or is under common control with, the specified person or entity, and the term “control” (including the terms controlling, controlled by and under common control with) means the possession, direct or indirect, of (i) the power to direct or cause the direction of the management and policies of an entity, whether through the ownership of voting securities, by contract or otherwise or (ii) 50% or more of the issued share capital of an entity.

Antengene (referred to as either "Antengene", "We", "Us" or "Our" in this Agreement) refers to Antengene Corporation Limited and its Affiliates.

Device means any device that can access the Service such as a computer, a cellphone or a digital tablet.

Service refers to the Website and its mobile applications.

Terms and Conditions (also referred as "Terms") mean these Terms and Conditions that form the entire agreement between You and Antengene regarding the use of the Service.

Third-party Social Media Service means any services or content (including data, information, products or services) provided by a third-party that may be displayed, included or made available by the Service.

Website refers to Antengene Website, accessible from https://www.antengene.com/

You means the individual accessing or using the Service, or Antengene, or other legal entity on behalf of which such individual is accessing or using the Service, as applicable.

2. Acknowledgment

2.1 These are the Terms and Conditions governing the use of this Service and the agreement that operates between You and Antengene. These Terms and Conditions set out the rights and obligations of all users regarding the use of the Service.

2.2 Your access to and use of the Service is conditioned on Your acceptance of and compliance with these Terms and Conditions. These Terms and Conditions apply to all visitors, users and others who access or use the Service. If You disagree with any part of these Terms and Conditions then You may not access the Service.

2.3 By accessing or using the Service You represent and warrant that (1) You have the legal capacity and You agree to be bound by these Terms and Conditions; (2) You are not a minor in the jurisdiction in which You reside; (3) You will not access or use the Service through automated or non-human means, whether through a bot, script, or otherwise; (4) You will not access or use the Service for any illegal or unauthorized purposes; and (5) Your use of the Service will not violate any applicable law or regulation.

2.4 Your access to and use of the Service is also conditioned on Your acceptance of and compliance with the Privacy Policy of Antengene. Our Privacy Policy describes Our policies and procedures on the collection, use and disclosure of Your personal information when You use the Service and tells You about Your privacy rights and how the law protects You. Please read Our Privacy Policy carefully before using Our Service.

3. Forward Looking Statement

3.1 The Service may contain forward-looking statements regarding Antengene’s future operating or financial performance, business plans and prospects, and Our expectations regarding clinical trials, development timelines, and discussions with regulatory authorities related to drugs and drug candidates under development by Us and Our collaboration partners.

3.2 These forward-looking statements relate only to the events or information as of the date on which the statements are made. You should read these statements completely and with the understanding that Our actual future results or performance may be materially different from what We expect. In these statements of, or references to, Our intentions or those of any of Our directors or Our Company are made as of the date of those statements. Any of these intentions may alter in light of future development. For a further discussion of these and other factors that could cause future results to differ materially from any forward-looking statement, see the section titled “Risk Factors” in Our periodic reports filed with the Hong Kong Stock Exchange and the other risks and uncertainties described in Antengene’s Annual Report, and subsequent filings with the Hong Kong Stock Exchange.

3.3 Except as required by law, We undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events.

4. Content and License

4.1 Antengene and its Affiliates, licensors, partners, providers, and their respective successors and assigns retain sole and exclusive ownership of all worldwide right, title and interest, including all copyrights, patent rights, trade secret rights, trademark rights, and other intellectual property and proprietary rights, in and to the Service, including all text, graphics and images, data, information, reports, software, tools, links and resources comprised in the Service or provided through the Service, as well as all technologies used by Antengene to provide and operate the Service.  Other than a limited license to use as provided below, You have and acquire no other right or license with respect to the Service or any portion or component thereof. Unless expressly authorized by applicable law or in writing by Antengene, You may not copy, reproduce, publicly perform or display, transmit, modify or otherwise create derivative works from, sell, distribute, or otherwise make unauthorized use of the Service or any portion or component thereof. Any unauthorized use of the Service or any portion or component thereof is strictly prohibited and may result in civil and/or criminal penalties. There are no implied rights or licenses granted to You under these Terms.

4.2 Subject to Your compliance with these Terms and Conditions and all applicable laws and regulations, Antengene grants You a revocable, non-exclusive, non-transferable, non-sublicensable, limited personal license to access the Service for Your lawful personal and noncommercial uses. As a condition of Your use of the Service, You agree not to: (a) take any action that imposes an unreasonable load on the Service’ infrastructure, (b) use any device, software or routine to interfere or attempt to interfere with the proper working of the Service or any activity being conducted on the Service, (c) attempt to decipher, decompile, disassemble or reverse engineer any of the software comprising or making up the Service, (d) delete or alter any material posted on the Service by Antengene or any other person or entity, or (e) frame or link to any of the materials or information available on the Service.

4.3 You acknowledge and agree that any data, questions, comments, suggestions, ideas, feedback, or other information provided by You to Antengene (“Submissions”) will be treated as non-confidential and shall become Our sole property. We shall own exclusive rights, including all intellectual property rights, and shall be entitled to the unrestricted use and dissemination of these Submissions for any lawful purpose, commercial or otherwise, without acknowledgment or compensation to You. You hereby waive all moral rights to any such Submissions, and You hereby warrant that any such Submissions are original with You or that You have the right to submit such Submissions. You agree there shall be no recourse against Us for any alleged or actual infringement or misappropriation of any proprietary right in Your Submissions. Your Submissions might be publicly accessible. Important and private information should be protected by You. Antengene is not liable for protection of privacy of email or other information transferred through the Internet or any other network that you may use.

5. Site Management

5.1 We reserve the right, but not the obligation, to: (1) monitor the Service for violations of these Terms and Conditions; (2) take appropriate legal action against anyone who, in Our sole discretion, violates the law or these Terms and Conditions, including without limitation, reporting such user to law enforcement authorities; (3) in Our sole discretion and without limitation, notice, or liability, to remove from the Service or otherwise disable all files and content that are excessive in size or are in any way burdensome to Our systems; and (4) otherwise manage the Service in a manner designed to protect Our rights and property and to facilitate the proper functioning of the Service.

5.2 We reserve the right to change, modify, or remove the contents of the Service at any time or for any reason at Our sole discretion without notice. However, we have no obligation to update any information on Our Service. We also reserve the right to modify or discontinue all or part of the Service without notice at any time. We will not be liable to You or any third party for any modification, suspension, or discontinuance of the Service.

5.3 We cannot guarantee the Service will be available at all times. We may experience hardware, software, or other problems or need to perform maintenance related to the Service, resulting in interruptions, delays, or errors. We reserve the right to change, revise, update, suspend, discontinue, or otherwise modify the Service at any time or for any reason without notice to You. You agree that we have no liability whatsoever for any loss, damage, or inconvenience caused by Your inability to access or use the Service during any downtime or discontinuance of the Service. Nothing in these Terms and Conditions will be construed to obligate Us to maintain and support the Service or to supply any corrections, updates, or releases in connection therewith.

6. Links to Other Websites

6.1 Our Service may contain links to third-party websites or services that are not owned or controlled by Antengene.

6.2 Antengene has no control over, and assumes no responsibility for, the content, privacy policies, or practices of any third-party websites or services. You further acknowledge and agree that Antengene shall not be responsible or liable, directly or indirectly, for any damage or loss caused or alleged to be caused by or in connection with the use of or reliance on any such content, goods or services available on or through any such websites or services.

6.3 We strongly advise You to read the terms and conditions and privacy policies of any third-party websites or services that You visit.

7. Termination

7.1 We may terminate or suspend Your access immediately, without prior notice or liability, for any reason whatsoever, including without limitation if You breach these Terms and Conditions.

7.2 Upon termination, Your right to use the Service will cease immediately.

8. Limitation of Liability

8.1 Notwithstanding any damages that You might incur, the entire liability of Antengene and any of its suppliers under any provision of this Terms and Your exclusive remedy for all of the foregoing shall be limited to the amount actually paid by You through the Service or USD100 if You haven't purchased anything through the Service.

8.2 TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, IN NO EVENT SHALL ANTENGENE OR ITS SUPPLIERS BE LIABLE FOR ANY SPECIAL, INCIDENTAL, INDIRECT, OR CONSEQUENTIAL DAMAGES WHATSOEVER (INCLUDING, BUT NOT LIMITED TO, DAMAGES FOR LOSS OF PROFITS, LOSS OF DATA OR OTHER INFORMATION, FOR BUSINESS INTERRUPTION, FOR PERSONAL INJURY, LOSS OF PRIVACY ARISING OUT OF OR IN ANY WAY RELATED TO THE USE OF OR INABILITY TO USE THE SERVICE, THIRD-PARTY SOFTWARE AND/OR THIRD-PARTY HARDWARE USED WITH THE SERVICE, OR OTHERWISE IN CONNECTION WITH ANY PROVISION OF THIS TERMS), EVEN IF ANTENGENE OR ANY SUPPLIER HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES AND EVEN IF THE REMEDY FAILS OF ITS ESSENTIAL PURPOSE.

8.3 YOU AGREE THAT ANY CAUSE OF ACTION OR CLAIM YOU MAY HAVE AGAINST ANTENGENE ARISING OUT OF OR RELATED TO THESE TERMS OR THE SERVICES OR ANY INFORMATION PROVIDED THROUGH THE SERVICES, MUST BE BROUGHT WITHIN ONE (1) YEAR AFTER THE CAUSE OF ACTION OR CLAIM ACCRUES, OR BE PERMANENTLY BARRED.

 

8.4 Some jurisdictions do not allow the exclusion of implied warranties or limitation of liability for incidental or consequential damages, which means that some of the above limitations may not apply. In these jurisdictions, each party's liability will be limited to the greatest extent permitted by law.

9. "AS IS" and "AS AVAILABLE" Disclaimer

9.1 THE SERVICE IS PROVIDED TO YOU "AS IS" AND "AS AVAILABLE" AND WITH ALL FAULTS AND DEFECTS WITHOUT WARRANTY OF ANY KIND. TO THE MAXIMUM EXTENT PERMITTED UNDER APPLICABLE LAW, ANTENGENE, ON ITS OWN BEHALF AND ON BEHALF OF ITS AFFILIATES AND ITS AND THEIR RESPECTIVE LICENSORS AND SERVICE PROVIDERS, EXPRESSLY DISCLAIMS ALL WARRANTIES, WHETHER EXPRESS, IMPLIED, STATUTORY OR OTHERWISE, WITH RESPECT TO THE SERVICE, INCLUDING ALL IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, TITLE AND NON-INFRINGEMENT, AND WARRANTIES THAT MAY ARISE OUT OF COURSE OF DEALING, COURSE OF PERFORMANCE, USAGE OR TRADE PRACTICE. WITHOUT LIMITATION TO THE FOREGOING, ANTENGENE PROVIDES NO WARRANTY OR UNDERTAKING, AND MAKES NO REPRESENTATION OF ANY KIND THAT THE SERVICE WILL MEET YOUR REQUIREMENTS, ACHIEVE ANY INTENDED RESULTS, BE COMPATIBLE OR WORK WITH ANY OTHER SOFTWARE, APPLICATIONS, SYSTEMS OR SERVICES, OPERATE WITHOUT INTERRUPTION, MEET ANY PERFORMANCE OR RELIABILITY STANDARDS OR BE ERROR FREE OR THAT ANY ERRORS OR DEFECTS CAN OR WILL BE CORRECTED.

9.2 WITHOUT LIMITING THE FOREGOING, NEITHER ANTENGENE NOR ANY OF ANTENGENE'S PROVIDER MAKES ANY REPRESENTATION OR WARRANTY OF ANY KIND, EXPRESS OR IMPLIED: (I) AS TO THE OPERATION OR AVAILABILITY OF THE SERVICE, OR THE INFORMATION, CONTENT, AND MATERIALS OR PRODUCTS INCLUDED THEREON; (II) THAT THE SERVICE WILL BE UNINTERRUPTED OR ERROR-FREE; (III) AS TO THE ACCURACY, RELIABILITY, OR CURRENCY OF ANY INFORMATION OR CONTENT PROVIDED THROUGH THE SERVICE; OR (IV) THAT THE SERVICE, ITS SERVERS, THE CONTENT, OR E-MAILS SENT FROM OR ON BEHALF OF ANTENGENE ARE FREE OF VIRUSES, SCRIPTS, TROJAN HORSES, WORMS, MALWARE, TIMEBOMBS OR OTHER HARMFUL COMPONENTS.

9.3 Some jurisdictions do not allow the exclusion of certain types of warranties or limitations on applicable statutory rights of a consumer, so some or all of the above exclusions and limitations may not apply to You. But in such a case the exclusions and limitations set forth in this section shall be applied to the greatest extent enforceable under applicable law.

10. Indemnification

You agree to defend, indemnify, and hold Antengene and its Affiliates, licensors, partners, providers, and their respective successors harmless from and against any claims, actions or demands, including, without limitation, reasonable legal and accounting fees, arising or resulting from Your breach of these Terms or Your access to, use or misuse of the Service. Antengene shall provide notice to You of any such claim, suit, or proceeding. Antengene reserves the right to assume the exclusive defense and control of any matter which is subject to indemnification under this section. In such case, You agree to cooperate with any reasonable requests assisting Antengene’s defense of such matter.

11. Governing Law

The laws of the State of New York, excluding its conflicts of law rules, shall govern this Terms and Your use of the Service. Your use of the Application may also be subject to other local, state, national, or international laws.

12. Disputes Resolution

If You have any concern or dispute about the Service, You agree to first try to resolve the dispute informally by contacting Antengene.

13. Compliance

You are solely responsible for ensuring compliance with the laws of Your specific jurisdiction. You expressly agree to comply with any applicable export restrictions under any applicable export control laws and not to export or re-export any part of the Service to countries or persons prohibited under such export control laws. By downloading any content of the Service, You are expressly agreeing that You are not in a country where such export is prohibited or are a person or entity for which such export is prohibited.

14. Translation Interpretation

These Terms and Conditions may have been translated if We have made them available to You on Our Service. You agree that the original English text shall prevail in the case of a dispute.

15. Changes to These Terms and Conditions

15.1 We reserve the right, at Our sole discretion, to modify or replace these Terms at any time. If a revision is material We will make reasonable efforts to provide at least 30 days' notice prior to any new terms taking effect. What constitutes a material change will be determined at Our sole discretion.

15.2 By continuing to access or use Our Service after those revisions become effective, You agree to be bound by the revised terms. If You do not agree to the new terms, in whole or in part, please stop using the Service.

16. Miscellaneous

16.1 If any provision of these Terms is held to be unenforceable or invalid, such provision will be changed and interpreted to accomplish the objectives of such provision to the greatest extent possible under the applicable law and the remaining provisions will continue in full force and effect.

16.2 Except as provided herein, the failure to exercise a right or to require performance of an obligation under these Terms shall not affect a party's ability to exercise such right or require such performance at any time thereafter nor shall the waiver of a breach constitute a waiver of any subsequent breach.

16.3 Visiting the Service, sending Us emails, and completing online forms constitute electronic communications. You consent to receive electronic communications, and You agree that all agreements, notices, disclosures, and other communications we provide to You electronically, via email and on the Service, satisfy any legal requirement that such communication be in writing.

16.4 These Terms and Conditions and any policies or operating rules posted by Us on the Service or in respect to the Service constitute the entire agreement and understanding between You and Us.

16.5 We may assign any or all of Our rights and obligations to others at any time without notice to You. We shall not be responsible or liable for any loss, damage, delay, or failure to act caused by any cause beyond Our reasonable control.

16.6 There is no joint venture, partnership, employment or agency relationship created between You and Us as a result of these Terms and Conditions or use of the Service.

16.7 You agree that these Terms and Conditions will not be construed against Us by virtue of having drafted them.

17. Contact Us

If You have any questions about these Terms and Conditions, You can contact Us:

· By email: legal@antengene.com